title: Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism.
abstract: Atorvastatin (AT) has been alternatively used for managing diabetic complications in clinic. However, AT-related therapeutic potentiality remains relatively unexplored, especially in diabetic nephropathy. This study aimed to investigate the underlying potentiality that AT exerted on anti-diabetic nephropathy role against streptozotocin (STZ)-induced kidney injury in rats. STZ-diabetic rats were intragastrically administered with AT (10, 20 mg/kg/d) for consecutive 8 weeks. The effects of AT on body weight, levels of blood glucose, lipometabolism, redox state, cellular metabolism, regulator factor and kidney morphological changes were monitored by routine measurement, biochemistry assay, PT-PCR analysis, ultrastructural and pathological observations, respectively. Compared with the diabetic nephropathy rats, AT elevated the body weight of diabetic nephropathy rats (P<0.01), effectively reduced the blood glucose level (P<0.01), increased the levels of insulin and high-density lipoprotein cholesterol (HDL-C) in plasma (P<0.01), and decreased the 24 h urine protein content and serum concentrations of low-density lipoprotein cholesterol (LDL-C) (P<0.01). Meanwhile, increase in kidney tissue, the intrarenal activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were enhanced, while the malonaldehyde (MDA) content was reduced (P<0.01). In addition, the expression of transforming growth factor beta 1 (TGF-β1) mRNA in kidney tissue was notably down-regulated (P<0.01). Furthermore, AT contributed to alleviating STZ-induced nephritic damages in rats. These results demonstrate that atorvastatin exerts the effective protective role against kidney injuries of STZ-induced diabetic nephropathy rat, which the underlying mechanisms are associated with ameliorating glyco, lipometabolism, enhancing antioxidant ability, and mitigating renal damage.
authors.affiliation: Department of Endocrinology, Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
authors.forename: Suxian
authors.initials: S
authors.lastname: Zhou
authors.affiliation: Department of Endocrinology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Zhao
authors.affiliation: Department of Endocrinology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, China.
authors.forename: Yingfang
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Endocrinology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, China.
authors.forename: Tingting
authors.initials: T
authors.lastname: Deng
authors.affiliation: Department of Endocrinology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, China.
authors.forename: Lihua
authors.initials: L
authors.lastname: Tian
authors.affiliation: Department of Neurology, Affiliated Hospital of Guilin Medical University, Guilin 541001, China. Electronic address: lihao_hospital@126.com.
authors.forename: Hao
authors.initials: H
authors.lastname: Li
mesh_terms: D000818:Animals; D000069059:Atorvastatin; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D011507:Proteinuria / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D017207:Rats, Sprague-Dawley; D013311:Streptozocin; D053773:Transforming Growth Factor beta1 / Q000235:genetics
chemical_list: D001786:Blood Glucose; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011758:Pyrroles; D012333:RNA, Messenger; D053773:Transforming Growth Factor beta1; D013311:Streptozocin; D000069059:Atorvastatin
keywords: Atorvastatin; Diabetic nephropathy; Metabolism; Renoprotection